GLP-1 therapy belongs to a class of medications called glucagon-like peptide-1 (GLP-1) agonists
Importantly, localized increases in GLP-1, such as that occur in the gut and portal vein, often have a more profound effect than systemic elevations, emphasizing the therapeutic potential of targeting regional activity rather than relying solely on systemic concentrations
Some of the most well-known GLP-1 receptor agonists include: Semaglutide (Ozempic, Wegovy): Originally developed for diabetes management, semaglutide has shown significant weight loss results
The dark side of GLP-1 receptor agonists primarily revolves around gastrointestinal issues, such as nausea
What happens if you inject too close to the belly button
Similarly, tirzepatide (Zepbound) demonstrated up to 22.5% weight loss in a 72-week trial with the same approach